Sophiris Bio, a La Jolla, Calif.-based biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial U.S. public offering of its common shares on the NASDAQ stock market.
The Company has also filed a preliminary short form prospectus with the securities regulatory authorities in British Columbia and Ontario in connection with the proposed offering. All common shares to be sold in the offering will be offered by Sophiris. The number of shares to be offered and the price range for the offering have not yet been determined.
Citigroup and Leerink Swann are acting as joint book-running managers for the offering. Stifel and Lazard Capital Markets are acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Citigroup Global Markets, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at firstname.lastname@example.org or by phone at 1-800-831-9146, and Leerink Swann (excluding the Canadian preliminary prospectus), Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by email at email@example.com or by phone at 1-800-808-7525.